Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1992 Jun;66(6):3466–3475. doi: 10.1128/jvi.66.6.3466-3475.1992

Mutations within the env gene of Mason-Pfizer monkey virus: effects on protein transport and SU-TM association.

B A Brody 1, E Hunter 1
PMCID: PMC241127  PMID: 1316462

Abstract

By deletion mutagenesis analyses, we have examined the contribution of the immunosuppressive peptide (ISP) region within the transmembrane (TM) protein of Mason-Pfizer monkey virus to viral maturation and infectivity. Deletion of the entire region (mutant D105) results in the production of an Env precursor that is transport defective and therefore unable to be processed to mature glycoproteins. This mutation results in the release of noninfectious virions devoid of surface glycoproteins. A second deletion that removes the most highly conserved 11 amino acids of the ISP (mutant D33) does not affect the production, transport, or processing of the Env precursor yet produces virions that are noninfectious. The mutation was shown to cause the loss of interaction between the surface (SU) and TM proteins and result in the efficient shedding of gp70 into the culture medium. The released gp70 protein was biologically active and could still bind with high specificity to susceptible target cells. Since the ISP domain may represent an area of contact between SU and TM, it could provide an additional explanation for the amino acid sequence homology observed within this region of a variety of retroviruses.

Full text

PDF
3466

Images in this article

3469Image
on p.3469
3470Image
on p.3470
3471Image
on p.3471
3472Image
on p.3472
3473Image
on p.3473

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arthur L. O., Gilden R. V., Marx P. A., Gardner M. B. Simian acquired immunodeficiency syndrome. Prog Allergy. 1986;37:332–352. doi: 10.1159/000318452. [DOI] [PubMed] [Google Scholar]
  2. Blochlinger K., Diggelmann H. Hygromycin B phosphotransferase as a selectable marker for DNA transfer experiments with higher eucaryotic cells. Mol Cell Biol. 1984 Dec;4(12):2929–2931. doi: 10.1128/mcb.4.12.2929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bosch J. V., Schwarz R. T., Ziemiecki A., Friis R. R. Oligosaccharide modifications and the site of processing of gPr92env, the precursor for the viral glycoproteins of Rous sarcoma virus. Virology. 1982 May;119(1):122–132. doi: 10.1016/0042-6822(82)90070-8. [DOI] [PubMed] [Google Scholar]
  4. Bradac J., Hunter E. Polypeptides of Mason-Pfizer monkey virus. II. Synthesis and processing of the env gene products. Virology. 1986 Apr 30;150(2):491–502. doi: 10.1016/0042-6822(86)90313-2. [DOI] [PubMed] [Google Scholar]
  5. Bryant M. L., Gardner M. B., Marx P. A., Maul D. H., Lerche N. W., Osborn K. G., Lowenstine L. J., Bodgen A., Arthur L. O., Hunter E. Immunodeficiency in rhesus monkeys associated with the original Mason-Pfizer monkey virus. J Natl Cancer Inst. 1986 Oct;77(4):957–965. [PubMed] [Google Scholar]
  6. Ceglowski W. S. Effect of leukemia virus infections on antibody formation and cellular immunity. Ann N Y Acad Sci. 1976;276:411–416. doi: 10.1111/j.1749-6632.1976.tb41666.x. [DOI] [PubMed] [Google Scholar]
  7. Chatterjee S., Bradac J., Hunter E. A rapid screening procedure for the isolation of nonconditional replication mutants of Mason-Pfizer monkey virus: identification of a mutant defective in pol. Virology. 1985 Feb;141(1):65–76. doi: 10.1016/0042-6822(85)90183-7. [DOI] [PubMed] [Google Scholar]
  8. Chen C., Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol. 1987 Aug;7(8):2745–2752. doi: 10.1128/mcb.7.8.2745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cianciolo G. J., Copeland T. D., Oroszlan S., Snyderman R. Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science. 1985 Oct 25;230(4724):453–455. doi: 10.1126/science.2996136. [DOI] [PubMed] [Google Scholar]
  10. Cianciolo G. J., Kipnis R. J., Snyderman R. Similarity between p15E of murine and feline leukaemia viruses and p21 of HTLV. Nature. 1984 Oct 11;311(5986):515–515. doi: 10.1038/311515a0. [DOI] [PubMed] [Google Scholar]
  11. Cianciolo G. J., Matthews T. J., Bolognesi D. P., Snyderman R. Macrophage accumulation in mice is inhibited by low molecular weight products from murine leukemia viruses. J Immunol. 1980 Jun;124(6):2900–2905. [PubMed] [Google Scholar]
  12. Copelan E. A., Rinehart J. J., Lewis M., Mathes L., Olsen R., Sagone A. The mechanism of retrovirus suppression of human T cell proliferation in vitro. J Immunol. 1983 Oct;131(4):2017–2020. [PubMed] [Google Scholar]
  13. Davis G. L., Hunter E. A charged amino acid substitution within the transmembrane anchor of the Rous sarcoma virus envelope glycoprotein affects surface expression but not intracellular transport. J Cell Biol. 1987 Sep;105(3):1191–1203. doi: 10.1083/jcb.105.3.1191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Einfeld D., Hunter E. Oligomeric structure of a prototype retrovirus glycoprotein. Proc Natl Acad Sci U S A. 1988 Nov;85(22):8688–8692. doi: 10.1073/pnas.85.22.8688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fine D. L., Landon J. C., Pienta R. J., Kubicek M. T., Valerio M. G., Loeb W. F., Chopra H. C. Responses of infant rhesus monkeys to inoculation with Mason-Pfizer monkey virus materials. J Natl Cancer Inst. 1975 Mar;54(3):651–658. [PubMed] [Google Scholar]
  16. Friedman H., Ceglowski W. S. Leukemia virus-induced immunosuppression. 8. Rapid depression of in vitro leukocyte migration after infection of mice with Friend leukemia virus. J Immunol. 1971 Dec;107(6):1673–1681. [PubMed] [Google Scholar]
  17. Gallaher W. R., Ball J. M., Garry R. F., Griffin M. C., Montelaro R. C. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses. 1989 Aug;5(4):431–440. doi: 10.1089/aid.1989.5.431. [DOI] [PubMed] [Google Scholar]
  18. Gallo R. C., Blattner W. A. Human T-cell leukemia/lymphoma viruses: ATL and AIDS. Important Adv Oncol. 1985:104–138. [PubMed] [Google Scholar]
  19. Gelderblom H. R., Hausmann E. H., Ozel M., Pauli G., Koch M. A. Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology. 1987 Jan;156(1):171–176. doi: 10.1016/0042-6822(87)90449-1. [DOI] [PubMed] [Google Scholar]
  20. Gelderblom H. R., Reupke H., Pauli G. Loss of envelope antigens of HTLV-III/LAV, a factor in AIDS pathogenesis? Lancet. 1985 Nov 2;2(8462):1016–1017. doi: 10.1016/s0140-6736(85)90570-7. [DOI] [PubMed] [Google Scholar]
  21. Gnann J. W., Jr, Nelson J. A., Oldstone M. B. Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol. 1987 Aug;61(8):2639–2641. doi: 10.1128/jvi.61.8.2639-2641.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Harris D. T., Cianciolo G. J., Snyderman R., Argov S., Koren H. S. Inhibition of human natural killer cell activity by a synthetic peptide homologous to a conserved region in the retroviral protein, p15E. J Immunol. 1987 Feb 1;138(3):889–894. [PubMed] [Google Scholar]
  23. Hebebrand L. C., Mathes L. E., Olsen R. G. Inhibition of concanavalin A stimulation of feline lymphocytes by inactivated feline leukemia virus. Cancer Res. 1977 Dec;37(12):4532–4533. [PubMed] [Google Scholar]
  24. Hebebrand L. C., Olsen R. G., Mathes L. E., Nichols W. S. Inhibition of human lymphocyte mitogen and antigen response by a 15,000-dalton protein from feline leukemia virus. Cancer Res. 1979 Feb;39(2 Pt 1):443–447. [PubMed] [Google Scholar]
  25. Hoover E. A., Mullins J. I., Quackenbush S. L., Gasper P. W. Experimental transmission and pathogenesis of immunodeficiency syndrome in cats. Blood. 1987 Dec;70(6):1880–1892. [PubMed] [Google Scholar]
  26. Hunter E., Hill E., Hardwick M., Bhown A., Schwartz D. E., Tizard R. Complete sequence of the Rous sarcoma virus env gene: identification of structural and functional regions of its product. J Virol. 1983 Jun;46(3):920–936. doi: 10.1128/jvi.46.3.920-936.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Hunter E., Swanstrom R. Retrovirus envelope glycoproteins. Curr Top Microbiol Immunol. 1990;157:187–253. doi: 10.1007/978-3-642-75218-6_7. [DOI] [PubMed] [Google Scholar]
  28. Kowalski M., Potz J., Basiripour L., Dorfman T., Goh W. C., Terwilliger E., Dayton A., Rosen C., Haseltine W., Sodroski J. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science. 1987 Sep 11;237(4820):1351–1355. doi: 10.1126/science.3629244. [DOI] [PubMed] [Google Scholar]
  29. Leamnson R. N., Halpern M. S. Subunit structure of the glycoprotein complex of avian tumor virus. J Virol. 1976 Jun;18(3):956–968. doi: 10.1128/jvi.18.3.956-968.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Mitani M., Cianciolo G. J., Snyderman R., Yasuda M., Good R. A., Day N. K. Suppressive effect on polyclonal B-cell activation of a synthetic peptide homologous to a transmembrane component of oncogenic retroviruses. Proc Natl Acad Sci U S A. 1987 Jan;84(1):237–240. doi: 10.1073/pnas.84.1.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Mullins J. I., Chen C. S., Hoover E. A. Disease-specific and tissue-specific production of unintegrated feline leukaemia virus variant DNA in feline AIDS. Nature. 1986 Jan 23;319(6051):333–336. doi: 10.1038/319333a0. [DOI] [PubMed] [Google Scholar]
  32. Nelson M., Nelson D. S., Cianciolo G. J., Snyderman R. Effects of CKS-17, a synthetic retroviral envelope peptide, on cell-mediated immunity in vivo: immunosuppression, immunogenicity, and relation to immunosuppressive tumor products. Cancer Immunol Immunother. 1989;30(2):113–118. doi: 10.1007/BF01665962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Nelson M., Nelson D. Inhibition of interleukin-2 production by tumor cell products and by CKS-17, a synthetic retroviral envelope peptide. Cancer Immunol Immunother. 1990;30(6):331–341. doi: 10.1007/BF01786882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Ogasawara M., Cianciolo G. J., Snyderman R., Mitani M., Good R. A., Day N. K. Human IFN-gamma production is inhibited by a synthetic peptide homologous to retroviral envelope protein. J Immunol. 1988 Jul 15;141(2):614–619. [PubMed] [Google Scholar]
  35. Orosz C. G., Zinn N. E., Olsen R. G., Mathes L. E. Retrovirus-mediated immunosuppression. I. FeLV-UV and specific FeLV proteins alter T lymphocyte behavior by inducing hyporesponsiveness to lymphokines. J Immunol. 1985 May;134(5):3396–3403. [PubMed] [Google Scholar]
  36. Reth M. Antigen receptor tail clue. Nature. 1989 Mar 30;338(6214):383–384. doi: 10.1038/338383b0. [DOI] [PubMed] [Google Scholar]
  37. Rhee S. S., Hui H. X., Hunter E. Preassembled capsids of type D retroviruses contain a signal sufficient for targeting specifically to the plasma membrane. J Virol. 1990 Aug;64(8):3844–3852. doi: 10.1128/jvi.64.8.3844-3852.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Rhee S. S., Hunter E. Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids. J Virol. 1987 Apr;61(4):1045–1053. doi: 10.1128/jvi.61.4.1045-1053.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Sanger F., Nicklen S., Coulson A. R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463–5467. doi: 10.1073/pnas.74.12.5463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Sommerfelt M. A., Weiss R. A. Receptor interference groups of 20 retroviruses plating on human cells. Virology. 1990 May;176(1):58–69. doi: 10.1016/0042-6822(90)90230-o. [DOI] [PubMed] [Google Scholar]
  41. Sonigo P., Barker C., Hunter E., Wain-Hobson S. Nucleotide sequence of Mason-Pfizer monkey virus: an immunosuppressive D-type retrovirus. Cell. 1986 May 9;45(3):375–385. doi: 10.1016/0092-8674(86)90323-5. [DOI] [PubMed] [Google Scholar]
  42. Tsai W. P., Oroszlan S. Novel glycosylation pathways of retroviral envelope proteins identified with avian reticuloendotheliosis virus. J Virol. 1988 Sep;62(9):3167–3174. doi: 10.1128/jvi.62.9.3167-3174.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Willey R. L., Bonifacino J. S., Potts B. J., Martin M. A., Klausner R. D. Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9580–9584. doi: 10.1073/pnas.85.24.9580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Wills J. W., Srinivas R. V., Hunter E. Mutations of the Rous sarcoma virus env gene that affect the transport and subcellular location of the glycoprotein products. J Cell Biol. 1984 Dec;99(6):2011–2023. doi: 10.1083/jcb.99.6.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Witte O. N., Tsukamoto-Adey A., Weissman I. L. Cellular maturation of oncornavirus glycoproteins: topological arrangement of precursor and product forms in cellular membranes. Virology. 1977 Feb;76(2):539–553. doi: 10.1016/0042-6822(77)90236-7. [DOI] [PubMed] [Google Scholar]
  46. Zoller M. J., Smith M. Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors. Methods Enzymol. 1983;100:468–500. doi: 10.1016/0076-6879(83)00074-9. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES